Monte Jade New England

Monte Jade Science and Technology Association of New England (MJNE) is a non-profit organization, established on May 22, 1992 by science and technology professionals in the New England area.

Currently, MJNE is in its 25th year and is part of the Global Monte Jade network along with other active chapters in the U.S. and overseas.  MJNE includes professionals with a wide variety of experiences and expertise in science, engineering, medical, legal and business, and has become an idea incubator to serve its community.

Brief History

Monte Jade’s was founded at Silicon Valley, CA in 1989 with the initial force to bring together the high-tech experts from the Bay Area and it’s neighboring cities.  “Monte Jade” was chosen to signify cross-cultural and technological foresight and excellence of the highest level.

Current State History

MJNE is part of the growing Monte Jade family; as of today, there is 14 active chapters around the world.

MJNE Facebook page: https://www.facebook.com/MonteJadeNE/

MJNE email: mjnewengland@gmail.com

SEAN YI-HSIANG HSU

President

Dr. Sean Yi-Hsiang Hsu is a Co-director and Assistant Professor at Harvard Medical School, Associate Member at BROAD Institute of MIT and Harvard. He is also an Assistant Professor at Program for Quantitative Genomics, Program of Molecular and Integrative Physiological Sciences, Harvard School of Public Health, Boston, MA.

His research focuses on (1) genetic contribution of common aging relevant disorders (such as osteoporosis, sarcopenic obesity, metabolic syndrome, type 2 diabetes and hypertension) using population-based next generation whole genome
sequencing, exome-sequencing and GWAS approaches; (2) statistical method development on multiple-phenotype association analyses; (3) integrative omics dataset using system genetics and bioinfomatic approaches and (4) identifying biomarkers of osteoporosis using
metabolomics.

YAOYU WANG

Vice President

CAROLYN HSU

Director

Carolyn specializes in Chemistry, Manufacturing and Controls (CMC) activities from preclinical to commercial launch for both small molecule and biologics. Over her 23 years in big pharma and small biotech, Carolyn has spanned multiple aspects of business including CMC program management, outsourcing to external contract manufacturing organizations/ testing labs, process development, process validation (PV)/ performance qualification (PPQ) for registration, and commercial manufacturing process support. She also led technical teams to prepare regulatory filing documents (IND/ IMPD/ BLA/ MAA), knowledge management and continuous improvement efforts. She has been recognized by her peers as a thorough, responsible and dedicated team player to achieve deliverables.

Carolyn is passionate about innovation and creativity. She is good at making possibilities real by taking unprecedented tasks and creating pathways to accomplish objectives, promoting communication across divisions inclusively. She facilitates cross-functional collaboration and has track records of success in digital transformation of business workflows for increasing productivity.  She integrated people, processes and technology by partnering with IT/ data scientists, automating workflows and designing real-time dashboard reporting for science & technology organization.

Carolyn received her Ph.D. in Chemistry from Michigan State University and B.S. in Chemistry from National Taiwan University. Outside of work, Carolyn is active in a wide array of communities. She enjoys organizing workshops and symposiums as well as exploring international culture. Carolyn has served on the Board of Directors for Monte Jade New England since 2011.

CRYSTAL SUNG

Director

Crystal Sung is the Scientific Director of Clinical Laboratory Sciences at Sanofi. She is directing a CLIA certified lab which provides clinical laboratory services and scientific expertise to support global R&D projects and drug development through its life cycle (phase 0-IV and post approval commitments).
Crystal received a B.S. degree in Medical Technology from National Taiwan University and a Ph.D. degree in Pathology, College of Medicine, The Ohio State University.
She completed her post-doctoral clinical research training at Northwestern University Medical School followed by Clinical Immunology Fellowship at Chicago Medical School/Evanston Hospital/Children’s Memorial Hospital. Prior to joining Genzyme, she was an Assistant Professor in Tzu-Chi Medical School, Taiwan. Crystal joined Genzyme in 2001 and took a scientific leadership role in RT-PCR/tandem mass spectrometry biomarker assay development/validation and implemented clinical testing to support
drug adverse event management. Crystal successfully led her team to establish a CLIA certified lab in 2007 to support drug post approval immunogenicity surveillance and efficacy monitoring. The lab was one of the first to have a high complexity CLIA lab operating within a biotechnology company.
Crystal has over 12 years of industry experience in Biologics Immunogenicity. She led a global biomarker management initiative in 2013 and serves as advisory group of biomarker and bioanalysis within Sanofi. She currently directs 5 functional groups: Clinical Immunology, Clinical Mass Spectrometry, Molecular Analysis, Sample Management and Investigative Clinical Immunology.

Crystal is a Diplomate of American Board of Medical Laboratory Immunology (ABMLI) and currently holds a New York State Department of Public Health certificate of qualification of Laboratory Director in Diagnostic Immunology and Clinical Chemistry.G

REX HUAN
Director

Rex Huang is a patent attorney in the Boston office of Fish & Richardson P.C. His practice includes general intellectual property management, patent strategy and analysis, supervision of domestic and foreign patent application programs, complex prosecution, opinions, re-examination, and due diligence projects. He emphasizes creative and strategic planning and implementation.

KERLIN PEI

Director

Kerlin Pei is a Program Manager at the Raytheon Company – Integrated Defense Systems at Andover, Massachusetts. Raytheon Company, with 2007 sales of $21.3 billion, is a technology leader specializing in defense, homeland security and other government markets throughout the world.

Po-Shun Lee

Director

Victor Tang

Director

HSIN-HAO SU

Director

Professor Hsin-hao is an associate Professor of Mathematics at Stonehill College. He obtained his PhD in mathmatics from Johns Hopkins University. His research interest is Homotopy Theory, Algebraic Algebra, and Graph Theory.

LISA KANG

Director

Lisa is a seasoned biostatistician, investor, mentor, and founder of both startups and non-profits. With over two decades of experience in the biotech industry, she is particularly proud of her involvement in the approval of the first rare disease drug. Throughout her career, Lisa has led numerous drugs to approval and currently serves as an early-stage startup consultant, focusing on supporting the transition of drugs to clinical trials, particularly in initiating First-In-Human (FIH) studies within the scope of clinical development operations.

Lisa holds a Bachelor of Science in Chemistry from the University of North Carolina at Chapel Hill, a Master’s in Biostatistics from Tulane University, and a Master’s in Clinical Service Operations from Harvard Medical School. She has held statistical positions at several leading pharmaceutical and biotechnology companies, including Pfizer, Genzyme, GlaxoSmithKline, Eli Lilly, Eisai, Proteostasis, and Lyndra. In addition, Lisa has made significant contributions to the scientific community through her publications in peer-reviewed medical journals.

JAIME TSUNG

Director

Dr. Jamie Tsung is a principal scientist with in product development and processing in the biopharmaceutical industry. Currently, she works for Momenta Pharmaceuticals. Prior to Momenta, she worked at Shire where her research is focused on product development for the CNS (Central Nervous System).

JENG-SHIN LEE

Director

Dr. Jeng-Shin Lee is the Chief Scientific Officer at AB Biosciences, Inc. Founded in 2007, AB Biosciences Inc. (ABB) is a development stage biotechnology company, seeking to apply its proprietary technologies in protein and antibody engineering, to a selected group of important druggable target proteins, with the ultimate goal of generating novel antibody molecules for diagnostic and therapeutic purposes.

Y.JENNY CHEN

Director

Jenny Chen focuses her practice on U.S. and foreign patent prosecution, opinion work, and counseling clients in the areas of biological, medical, and pharmaceutical sciences. She is currently an Associate at Wolf Greenfield. Ms. Chen has worked on projects related to diagnosis and treatment of various diseases and disorders, vaccine technologies, drug discovery, antibiotic biosynthesis, medical implants, gene- and cell-based therapies, pharmaceutical formulations, and herb extracts.

HANK HUNGYUN LIN

Director

Hank is currently a Principal Scientist of Pfizer in Cambridge, MA. He represents drug safety within project teams in multiple therapeutic areas; and provides development and assessment of integrated biomarkers in support of both efficacy and toxicity biomarker needs in drug discovery and safety. Hank received his M.S. in Toxicology from National Taiwan University and his Ph.D. in Pathology and Laboratory Medicine from University of Rochester Medical School where he initiated his professional interests in metabolic syndrome and reproductive endocrinology.

Prior to joining Pfizer, Hank has held positions in several biomedical companies including Taiwan Biotech Co., Vaxin, AstraZeneca; providing expertise and technical skills for developing strategic initiatives of integrated biomarkers assessing mechanistic insight of target organ toxicities. He has published papers in basic and applied pathology, molecular toxicology, and endocrinology.